Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome

Gerontology

Volumn 53, Issue 6, 2008, Pages 329-339

  Dupuy, A M ^a,b   Jaussent, I ^b   Lacroux, A ^c   Durant, R ^d   Cristol, J P ^a   Delcourt, C ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b INSERM   (France)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d CHU   (France)

Author keywords

Adipose tissue; Atherosclerosis; C reactive protein; Inflammation; Waist circumference

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ABDOMINAL FAT; ADIPOCYTE; ADULT; AGED; AGING; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; FRANCE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SMOKING; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

AGED; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEX FACTORS; SMOKING; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 43449129738     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103555     Document Type: Article

References (64)

1. Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, Tracy RP: The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001;50:2384-2389.
2. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
3. Ridker PM, Buring JE, Cook NR, Rifai N: Creactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
4. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004;110:380-385.
5. Venugopal SK, Devaraj S, Jialal I: Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005;14:33-37.
6. Strandberg TE, Tilvis RS: C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol 2000;20:1057-1060.
7. Chenillot O, Henny J, Steinmetz J, Herbeth B, Wagner C, Siest G: High-sensitivity C-reactive protein: biological variations and reference limits. Clin Chem Lab Med 2000;38:1003-1011.
8. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, Kritchevsky SB: Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-2418.
9. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-512.
10. Taaffe DR, Harris TB, Ferrucci L, Rowe J, Seeman TE: Cross-sectional and prospective relationships of interleukin-6 and C-reactive protein with physical performance in elderly persons: MacArthur studies of successful aging. J Gerontol A Biol Sci Med Sci 2000;55:M709-M715.
11. Cankurtaran M, Halil M, Yavuz BB, Dagli N, Oyan B, Ariogul S: Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr 2006;42:35-45.
12. Delcourt C, Diaz JL, Ponton-Sanchez A, Papoz L: Smoking and age-related macular degeneration. The POLA Study. Pathologies Oculaires Liées àl'Age. Arch Ophthalmol 1998;116:1031-1035.
13. Dupuy AM, Badiou S, Descomps B, Cristol JP: Immunoturbidimetric determination of C-reactive protein (CRP) and high-sensitivity CRP on heparin plasma. Comparison with serum determination. Clin Chem Lab Med 2003;41:948-949.
14. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E: Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-450.
15. Ridker PM, Cook N: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-1959.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
17. Defay R, Delcourt C, Ranvier M, Lacroux A, Papoz L: Relationships between physical activity, obesity and diabetes mellitus in a French elderly population: the POLA Study. Pathologies Oculaires Liées àl'Age. Int J Obes Relat Metab Disord 2001;25:512-518.
18. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-2681.
19. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
20. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
21. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT: C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-1410.
22. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM: Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-2681.
23. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
24. Rathmann W, Haastert B, Icks A, Giani G, Holle R, Koenig W, Lowel H, Meisinger C: Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: the KORA Survey 2000. Diabetes Care 2006;29:461.
25. Scuteri A, Najjar SS, Morrell CH, Lakatta EG; Cardiovascular Health Study: The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events:the Cardiovascular Health Study. Diabetes Care 2005;28:882-887.
26. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-443.
27. Ascaso JF, Romero P, Real JT, Lorente RI, Martinez-Valls J, Carmena R: Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med 2003;14:101-106.
28. Balkau B: An epidemiologic survey from a network of French Health Examination Centres (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome (in French). Rev Epidémiol SantéPublique 1996;44:373-375.
29. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
30. Scott CL: Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003;92(1A):35i-42i.
31. Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E; the DESIR Study Group: Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: The DESIR Study. Atherosclerosis 2007;190:84-89.
32. Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM: Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-2021.
33. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, Muche R, Brenner H, Koenig W: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000;23:1835-1839.
34. Black PH: The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003;17:350-364.
35. Haffner S, Cassells HB: Metabolic syndrome - a new risk factor of coronary heart disease? Diabetes Obes Metab 2003;5:359-370.
36. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V: Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002;165:285-292.
37. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
38. Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM: The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-1415.
39. Despres JP:Intra-abdominal obesity: an untreated risk factor for type 2 diabetes and cardiovascular disease. J Endocrinol Invest 2006;29(3 Suppl):77-82.
40. Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006;38:52-63.
41. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y: Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004;28:674-679.
42. Santos AC, Lopes C, Guimaraes JT, Barros H: Central obesity as a major determinant of increased high-sensitivity C-reactive protein in metabolic syndrome. Int J Obes (Lond) 2005;29:1452-1456.
43. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC: C-reactive protein and its relation to cardiovascular risk factors: a population-based cross-sectional study. BMJ 1996;312:1061-1065.
44. Koenig W, Sund M, Fröhlich M, Fischer HG, Lowel H, Döring A, Hutchinson WL, Pepys MB: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
45. Yudkin JS, Yajnik CS, Mohamed-Ali V, Bulmer K: High levels of circulating proinflammatory cytokines and leptin in urban, but not rural, Indians. A potential explanation for increased risk of diabetes and coronary heart disease. Diabetes Care 1999;22:363-364.
46. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T: Association of markers of systemic inflammation, C-reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health 2003;57:730-733.
47. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17:1121-1127.
48. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH: Comparison of serum concentrations of C-reactive protein, TNF-alpha, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 2004;64:99-106.
49. Rohde LE, Hennekens CH, Ridker PM: Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:1018-1022.
50. Chae CU, Lee RT, Rifai N, Ridker PM: Blood pressure and inflammation in apparently healthy men. Hypertension 2001;38:399-403.
51. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK: Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138:891-897.
52. Lyon CJ, Law RE, Hsueh WA: Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144:2195-2200.
53. Ferrannini E, Natali A: Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991;121(4 Pt 2):1274-1282.
54. Gray RS, Fabsitz RR, Cowan LD, Lee ET, Howard BV, Savage PJ: Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 1998;148:869-878.
55. Raikkonen K, Lassila R, Keltikangas-Jarvinen L, Hautanen A: Association of chronic stress with plasminogen activator inhibitor-1 in healthy middle-aged men. Arterioscler Thromb Vasc Biol 1996;16:363-367.
56. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
57. Das S, Shahmanesh M, Stolinski M, Shojaee-Moradie F, Jefferson W, Jackson NC, Cobbold M, Nightingale P, Umpleby AM: In treatment-naive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 2006;49:538-542.
58. Calabro P, Chang DW, Willerson JT, Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005;46:1112-1113.
59. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW:C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978.
60. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, OkamotoY, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
61. Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of Creactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671-674.
62. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ, Hattersley AT, Ebrahim S, Lowe GD, Rumley A, Davey Smith G: C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 2005;366:1954-1959.
63. Hingorani A, Humphries S: Nature's randomised trials. Lancet 2005;366:1906-1908.
64. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-419.